WallStSmart

Sibanye Gold Ltd ADR (SBSW)vsVersamet Royalties Corporation Common Stock (VMET)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Sibanye Gold Ltd ADR generates 222171% more annual revenue ($164.89B vs $74.18M). VMET leads profitability with a 49.9% profit margin vs 9.8%. SBSW trades at a lower P/E of 8.0x. VMET earns a higher WallStSmart Score of 60/100 (C+).

SBSW

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.7Quality: 6.5
Piotroski: 6/9Altman Z: 1.37

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.0Value: 5.3Quality: 4.5
Piotroski: 5/9Altman Z: 1.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SBSW4 strengths · Avg: 9.5/10
P/E RatioValuation
8.0x10/10

Attractively priced relative to earnings

Revenue GrowthGrowth
64.3%10/10

Revenue surging 64.3% year-over-year

Free Cash FlowQuality
$16.30B10/10

Generating 16.3B in free cash flow

Operating MarginProfitability
29.9%8/10

Strong operational efficiency at 29.9%

VMET5 strengths · Avg: 9.6/10
Profit MarginProfitability
49.9%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
58.0%10/10

Strong operational efficiency at 58.0%

Revenue GrowthGrowth
391.9%10/10

Revenue surging 391.9% year-over-year

EPS GrowthGrowth
2123.0%10/10

Earnings expanding 2123.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

SBSW3 concerns · Avg: 2.0/10
Return on EquityProfitability
-16.3%2/10

ROE of -16.3% — below average capital efficiency

EPS GrowthGrowth
-38.2%2/10

Earnings declined 38.2%

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

VMET2 concerns · Avg: 2.5/10
Market CapQuality
$926.14M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : SBSW

The strongest argument for SBSW centers on P/E Ratio, Revenue Growth, Free Cash Flow. Revenue growth of 64.3% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.

Bear Case : SBSW

The primary concerns for SBSW are Return on Equity, EPS Growth, Altman Z-Score.

Bear Case : VMET

The primary concerns for VMET are Market Cap, Altman Z-Score.

Key Dynamics to Monitor

SBSW profiles as a hypergrowth stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 391.9% — sustainability is the question.

SBSW generates stronger free cash flow (16.3B), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SBSW scores higher overall (60/100 vs 60/100) and 64.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sibanye Gold Ltd ADR

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Sibanye Stillwater Limited is a precious metals mining company in South Africa, the United States, Zimbabwe, Canada and Argentina. The company is headquartered in Weltevreden Park, South Africa.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?